Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.47 |
| ▸ | CNR2 | P34972 | 15/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7588136 | 0.88 | CNR1 (0.44) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL2464792 | 0.88 | CNR2 (0.44) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL2467398 | 0.87 | CNR2 (0.46) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL673359 | 0.87 | CNR1 (0.40) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL9408867 | 0.86 | CNR2 (0.42) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL22289027 | 0.86 | CNR1 (0.42) | CNR1CNR2NPC1RAB9AGPR18 | |
| SCHEMBL258641 | 0.86 | CNR1 (0.41) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL9190250 | 0.85 | POLB (0.39) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL224924 | 0.83 | CNR1 (0.38) | CNR1CNR2NPC1RAB9ALMNA | |
| SCHEMBL13370057 | 0.83 | CNR1 (0.38) | CNR1CNR2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62081376-A | — | — | None | — | — | JP | disclosed |
| US-9034955-B2 | High molecular weight nonpolar benzotriazoles | BASF SE (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-2430089-B1 | HIGH MOLECULAR WEIGHT NON-POLAR BENZOTRIAZOLES | BASF SE (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2430089-A2 | HIGH-MOLECULAR NON-POLAR BENZTRIAZOLES | BASF SE (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059095-A1 | HIGH MOLECULAR WEIGHT NONPOLAR BENZOTRIAZOLES | BASF SE (DE) | 2012-03-08 | — | — | US | disclosed |
| WO-2010130752-A2 | HIGH-MOLECULAR NON-POLAR BENZTRIAZOLES | BASF SE (DE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2006090917-A2 | ULTRAVIOLET ABSORBING POLYMER FOR HIGH LIGHT RESISTANT RECORDING MATERIALS | NIPPON SHOKUBAI CO., LTD. (JP) | 2006-08-31 | — | — | WO | disclosed |
| US-6361764-B2 | ULTRAVIOLET LIGHT SCREENING AGENTS; COSMETICS | SOCIETE L'OREAL S.A. (FR) | 2002-03-26 | — | — | US | disclosed |
| US-20020010179-A1 | Novel insoluble S-triazine derivatives, process for their preparation, compositions containing them and uses thereof | RICHARD HERVE (FR) | 2002-01-24 | — | — | US | disclosed |
| JP-S6281376-A | BENZOTRIAZOLE COMPOUND | ADEKA ARGUS CHEM CO LTD | 1987-04-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059095-A1 | HIGH MOLECULAR WEIGHT NONPOLAR BENZOTRIAZOLES | SULT1A1, TPST2, SULT2A1 | CNR1 2926/4885CNR2 1930/4885NPC1 4231/4885 |
| US-20020010179-A1 | Novel insoluble S-triazine derivatives, process for their preparation, compositions containing them and uses thereof | TST, TYR, TPST2 | CNR1 4633/4885CNR2 4146/4885NPC1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.